Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Anoro Ellipta (umeclidinium/vilanterol) and Breo Ellipta (fluticasone/vilanterol) are both inhalers used to manage chronic obstructive pulmonary disease (COPD), but they have some key differences. Anoro Ellipta combines a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA), while Breo Ellipta combines an inhaled corticosteroid (ICS) and a LABA. This means Anoro Ellipta focuses on relaxing airway muscles and opening airways, whereas Breo Ellipta also reduces inflammation in the lungs. Anoro Ellipta is only used for COPD, but Breo Ellipta can also be used for asthma. Breo Ellipta has a generic version available, making it potentially more affordable than Anoro Ellipta, which does not have a generic form. Additionally, you need to rinse your mouth after using Breo Ellipta to prevent fungal infections, a step not required with Anoro Ellipta. Both inhalers are taken once daily and are not suitable for sudden breathing problems.
Breo is a combination inhaler used for maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults and children. It contains two active ingredients, fluticasone (an inhaled corticosteroid, or ICS) and vilanterol (a long-acting beta agonist, or LABA). Breo Ellipta (fluticasone / vilanterol) is inhaled through the mouth once per day. It's available as a lower-cost generic. Side effects can differ based on your age and your Breo Ellipta (fluticasone / vilanterol) dose, but generally include upper respiratory tract infections, sore throat, and headache.